breast
cancer
heterogen
diseas
increas
incid
worldwid
bianchini
et
al
three
marker
aberrantli
express
breast
cancer
use
target
therapi
clinic
includ
hormon
receptor
estrogen
er
progesteron
pgr
human
epiderm
growth
factor
receptor
tripleneg
breast
cancer
tnbc
character
tumor
lack
er
pgr
express
repres
approxim
breast
cancer
case
collignon
et
al
tnbc
belong
basallik
subtyp
breast
cancer
associ
higher
genet
instabl
molecul
target
therapi
far
alcalacorona
et
al
chemotherapi
major
treatment
patient
tnbc
bianchini
et
al
though
standard
anthracyclin
taxanebas
chemotherapi
achiev
patholog
complet
respons
pcr
patient
earli
stage
tnbc
von
minckwitz
et
al
mani
patient
tnbc
respond
chemotherapi
rel
poor
outcom
prognosi
bonotto
et
al
moreov
sever
group
current
investig
chemoresist
pathway
tnbc
cell
suggest
chemoresist
still
challeng
problem
advanc
patient
tnbc
loi
et
al
wein
loi
protein
kinas
play
crucial
role
signal
transduct
cell
prolifer
surviv
migrat
common
featur
cancer
cell
aberr
express
activ
kinas
may
promot
tumorigenesi
malign
drug
resist
sever
oncogen
kinas
discov
differ
type
cancer
exampl
bcrabl
play
role
chronic
myeloid
leukemia
epiderm
growth
factor
receptor
egfr
lung
cancer
breast
cancer
braf
mutat
melanoma
ascierto
et
al
highli
select
inhibitor
kinas
also
develop
cancer
treatment
target
therapi
knight
et
al
note
approxim
kinas
gene
human
genom
cheng
et
al
kinas
well
studi
variou
type
cancer
littl
known
role
kinas
cancer
malign
drug
resist
particularli
tnbc
cell
gene
silenc
small
interf
rna
sirna
provid
power
tool
identifi
novel
regul
requir
mani
biolog
process
cell
surviv
death
gao
et
al
examin
kinas
repres
potenti
chemoresist
gene
tnbc
cell
foulk
et
al
use
cell
express
luciferas
monitor
cell
viabil
live
cell
screen
kinom
sirna
librari
identifi
potenti
drug
resist
kinas
tnbc
cell
treat
chemotherapi
genet
pharmacolog
ablat
src
kinas
diminish
phosphoryl
downstream
effector
akt
enhanc
sensit
tnbc
cell
chemotherapeut
drug
coexpress
high
level
src
associ
poor
prognosi
patient
tnbc
suggest
combin
therapi
src
inhibitor
chemotherapeut
drug
might
benefici
srcexpress
patient
tnbc
breast
cancer
cell
cultur
dmem
fb
streptomycin
iu
penicillin
lglutamin
air
gene
knockdown
sirna
cell
transfect
nm
scrambl
sirna
sirna
src
kinas
dharmacon
h
use
lipofectamin
rnaimax
invitrogen
lentivir
infect
cell
seed
plate
transfect
system
bioscienc
encod
luciferas
express
vector
scrambl
shrna
shrna
src
use
lipofectamin
invitrogen
h
transfect
cell
rins
media
incub
h
supernat
use
infect
cell
maintain
cultur
puromycin
ad
everi
day
obtain
stabl
cell
line
live
cell
viabil
assay
sirna
screen
cell
harbor
luciferas
plasmid
seed
well
white
plate
contain
nm
scrambl
sirna
kinom
sirna
librari
sirna
gene
thermo
fisher
scientif
rnaimax
invitrogen
h
cell
mix
dluciferin
promega
treat
without
doxorubicin
h
net
luminesc
signal
rlu
h
monitor
reflect
cell
viabil
measur
atp
level
cell
without
luciferas
report
plasmid
cell
treat
dasatinib
selleckchem
presenc
absenc
doxorubicin
calbiochem
h
mix
celltit
glo
promega
min
luminesc
signal
read
fluoroskan
ascent
fl
reader
thermo
fisher
scientif
cell
seed
densiti
nanocultur
plate
scivax
corpor
kanagawa
japan
presenc
nm
sirna
cell
cultur
day
tumorspher
format
tumorspher
treat
anticanc
drug
h
stain
calcein
green
ethidium
red
livedead
viabilitycytotox
kit
thermo
fisher
scientif
live
dead
cell
popul
respect
cell
treat
without
methanol
min
consid
rel
control
dead
live
cell
live
dead
cell
observ
microscopi
quantit
fluoroskan
ascent
fl
reader
thermo
fisher
scientif
previous
describ
liu
et
al
cell
transfect
nm
scrambl
sirna
sirna
kinas
h
cell
harvest
extract
total
rna
trizol
reagent
invitrogen
rna
reversetranscrib
superscript
ii
rnase
hrevers
transcriptas
invitrogen
mrna
level
gene
amplifi
specif
primer
sybr
green
master
mix
appli
biosystem
result
analyz
steponeplustm
system
appli
biosystem
use
gapdh
normal
control
primer
sequenc
provid
upon
request
cell
briefli
rins
pb
lyse
ripa
buffer
mm
tri
cl
ph
mm
nacl
sodium
deoxychol
sd
proteas
inhibitor
cocktail
cell
lysat
resolv
sdspage
transfer
electrophoret
onto
nitrocellulos
membran
membran
block
bovin
serum
albumin
bsa
antiphosphoserin
antibodi
casein
pb
antibodi
membran
incub
primari
antibodi
includ
antisrc
cell
signal
antipsrc
cell
signal
cell
signal
antiactb
sigma
overnight
protein
probe
hrplabel
secondari
antibodi
detect
ecl
reagent
membran
scan
analyz
protein
express
imag
system
uvp
upland
ca
unit
state
breast
cancer
cell
seed
plate
densiti
cellswel
presenc
scrambl
sirna
sirna
cultur
media
renew
everi
day
coloni
format
cell
coloni
fix
paraformaldehyd
stain
crystal
violet
wv
count
determin
cytotox
effect
cell
data
report
mean
sem
least
three
independ
experi
compar
cell
viabil
control
srcsilenc
cell
nonparametr
student
ttest
use
evalu
signific
analyz
gene
express
tnbc
patient
dataset
obtain
ucsc
xena
wilcoxon
signedrank
test
use
evalu
differ
level
src
kinas
tumor
correspond
tumor
adjac
normal
tissu
ensur
group
enough
case
surviv
analys
roc
percentil
cutoff
set
src
respect
cumul
surviv
curv
estim
use
method
univari
multivari
cox
proport
hazard
model
use
crude
adjust
hazard
ratio
respect
p
consid
signific
tnbc
cell
line
reportedli
resist
mani
anticanc
drug
totaryjain
et
al
yu
et
al
evalu
kinas
involv
chemoresist
tnbc
cell
cell
treat
chemotherapeut
drug
camptothecin
doxorubicin
presenc
absenc
staurosporin
st
figur
pan
kinas
inhibitor
wildli
suppress
mani
kinas
low
dose
meggio
et
al
st
reduc
cell
viabil
synerg
cytotox
effect
chemotherapeut
drug
particularli
doxorubicin
figur
suggest
kinas
may
play
role
chemoresist
cell
examin
kinas
involv
surviv
doxorubicintr
cell
cell
express
luciferas
use
monitor
cell
viabil
live
cell
screen
kinom
sirna
librari
presenc
absenc
doxorubicin
figur
select
toprank
gene
due
knockdown
gene
enhanc
cytotox
doxorubicin
cell
like
respons
resist
effect
doxorubicin
tnbc
cell
figur
knockdown
effici
gene
confirm
realtim
pcr
figur
gene
confirm
parent
tnbc
cell
cell
viabil
measur
celltit
glo
figur
b
although
knockdown
sever
gene
significantli
enhanc
doxorubicininduc
cytotox
cell
silenc
src
kinas
augment
doxorubicininduc
cytotox
cell
figur
b
also
examin
kinom
hit
nontnbc
breast
cancer
cell
includ
cell
figur
gene
involv
chemoresist
vari
differ
breast
cancer
cell
line
nevertheless
knockdown
src
kinas
enhanc
cytotox
doxorubicin
cell
figur
furthermor
knockdown
src
determin
chemoresist
effect
tnbc
cell
tumorspher
cultur
model
mimic
vivo
condit
featur
cancer
stem
cell
shaheen
et
al
silenc
src
decreas
live
cell
popul
increas
dead
cell
popul
tnbc
cell
expos
chemotherapeut
drug
includ
camptothecin
doxorubicin
figur
verifi
knockdown
effici
src
kinas
mrna
level
protein
level
protein
level
src
kinas
determin
cell
transfect
sirna
src
kinas
immunoblot
figur
srcsilenc
cell
significantli
increas
sensit
doxorubicin
cell
dosedepend
manner
figur
moreov
clonogen
assay
result
show
number
coloni
decreas
doxorubicintr
srcsilenc
cell
combin
sirna
src
doxorubicin
treatment
complet
abrog
coloni
format
cell
figur
avoid
side
effect
transient
transfect
gener
src
stabl
knockdown
cell
shrna
src
cell
figur
similar
effect
sirna
cell
viabil
coloni
form
abil
stabli
srcsilenc
tnbc
cell
sensit
doxorubicin
treatment
control
cell
figur
anoth
src
highli
express
activ
tnbc
cell
line
even
resist
doxorubicin
figur
suggest
src
might
associ
chemoresist
tnbc
cell
src
first
discov
oncogen
tyrosin
kinas
due
abil
promot
tumor
initi
malign
src
kinas
lead
drug
resist
cancer
cell
target
therapi
activ
sever
downstream
effector
particularli
akt
zhang
yu
addit
recent
studi
indic
src
trigger
ubiquitin
degrad
protein
bik
rasraferk
pathway
attenu
apoptosi
cell
stress
lopez
et
al
ballesta
et
al
identifi
potenti
molecul
involv
chemoresist
src
cell
transfect
sirna
src
treat
doxorubicin
figur
silenc
src
kinas
larg
decreas
protein
level
total
phosphoryl
src
cell
addit
phosphoryl
akt
accordingli
diminish
cell
without
treatment
doxorubicin
figur
likewis
similar
result
seen
akt
protein
level
srcsilenc
cell
figur
nevertheless
bik
protein
level
unexpectedli
decreas
src
knockdown
cell
slightli
increas
cell
figur
addit
dasatinib
select
src
famili
kinas
inhibitor
attenu
phosphoryl
akt
cell
figur
dasatinib
inhibit
cell
viabil
enhanc
doxorubicin
sensit
cell
figur
ectop
express
constitut
activ
form
ca
resist
doxorubicin
domin
neg
form
dn
cell
figur
suggest
signal
may
confer
resist
doxorubicin
tnbc
cell
inspect
relationship
src
patient
surviv
analyz
src
express
level
tnbc
dataset
obtain
cancer
genom
atla
tcga
src
gene
express
tumor
tissu
patient
tnbc
significantli
higher
tumor
adjac
normal
tissu
figur
p
wilcoxon
signedrank
test
moreov
plot
use
analyz
relationship
src
gene
express
overal
surviv
diseasefre
surviv
patient
tnbc
figur
c
although
src
express
level
signific
correl
either
overal
diseasefre
surviv
patient
tnbc
figur
c
stratif
analysi
show
high
src
express
nearli
significantli
associ
shorter
overal
surviv
patient
earli
patholog
stage
ii
diseas
figur
e
examin
associ
coexpress
src
surviv
patient
coexpress
level
src
evalu
use
univari
multivari
cox
proport
hazard
model
tabl
tumor
tissu
high
coexpress
src
significantli
associ
shorter
overal
surviv
univari
multivari
analys
tabl
crude
hazard
ratio
chr
p
adjust
hazard
ratio
ahr
p
coexpress
statist
signific
diseasefre
surviv
tabl
analysi
stratif
model
indic
high
coexpress
level
src
associ
poor
overal
surviv
earli
figur
ii
p
advanc
iii
iv
p
patholog
stage
although
trend
associ
high
coexpress
src
poor
diseasefre
surviv
statist
signific
relationship
like
due
limit
sampl
size
group
specif
biomark
target
tnbc
chemotherapi
thu
far
lead
poor
outcom
patient
tnbc
kinas
involv
mani
biolog
process
associ
catabol
homeostasi
diseas
sever
kinas
identifi
oncogen
promot
tumorigenesi
resist
radiat
chemotherapeut
agent
target
oncogen
kinas
either
monoclon
antibodi
small
molecular
inhibitor
provid
promis
antitumor
effect
howev
littl
known
role
kinas
drug
resist
tnbc
cell
herein
screen
kinom
sirna
librari
chemoresist
kinas
tnbc
cell
report
follow
find
first
src
kinas
resist
kinas
tnbc
cell
respons
chemotherapeut
drug
doxorubicin
second
ablat
src
reduc
phosphoryl
akt
tnbc
cell
src
highli
activ
tnbc
cell
also
resist
doxorubicin
third
src
express
higher
tumor
tissu
compar
adjac
normal
tissu
patient
tnbc
high
coexpress
src
associ
poor
prognosi
suggest
axi
might
involv
chemoresist
tnbc
cell
genomewid
screen
sirna
librari
employ
identifi
mani
novel
regul
associ
diseas
pololik
kinas
cancer
hu
et
al
subunit
coatom
protein
complex
viru
infect
de
wild
et
al
dualspecif
tyrosin
phosphoryl
regul
kinas
neurodegen
diseas
azorsa
et
al
although
screen
system
provid
power
tool
biomed
research
may
bias
primari
valid
assay
use
cell
primari
assay
valid
potenti
gene
tnbc
cell
sever
gene
appear
involv
chemoresist
cell
gene
exert
effect
tnbc
cell
serinethreonineprotein
kinas
ctermin
src
kinas
csk
ro
protooncogen
kinas
may
overexpress
activ
cell
cell
receptor
tyrosin
kinas
contain
ntermin
extracellular
domain
ctermin
kinas
domain
acquaviva
et
al
gene
rearrang
utr
region
mani
differ
gene
occur
sever
cancer
cell
activ
downstream
effector
promot
tumorigenesi
includ
erk
akt
davi
doebel
result
suggest
activ
may
involv
doxorubicin
resist
cell
cell
studi
requir
examin
differenti
role
tnbc
cell
moreov
dasatinib
suppress
chemoresist
chondrosarcoma
cell
particularli
cell
mutat
van
oosterwijk
et
al
current
studi
also
show
srcsilenc
breast
cancer
cell
mutat
cell
rel
sensit
doxorubicin
cell
wildtyp
importantli
patient
tnbc
mutat
liu
et
al
though
mutat
may
involv
resist
mechan
dna
damag
drug
sever
mechan
might
also
confer
chemoresist
tnbc
cell
thu
investig
chemoresist
target
tnbc
cell
mutat
would
abl
reflect
situat
clinic
set
howev
role
srcmodul
chemoresist
breast
cancer
cell
requir
work
verifi
src
tyrosin
kinas
overexpress
tnbc
promot
receptor
tyrosin
kinas
phosphoryl
affect
cell
adhes
migrat
hochgraf
et
al
src
protein
level
higher
tumor
tissu
patient
tnbc
patient
nontnbc
tryfonopoulo
et
al
combin
treatment
dasatinib
cisplatin
synergist
effect
cancer
suppress
tnbc
cell
tryfonopoulo
et
al
support
notion
src
might
involv
chemoresist
tnbc
cell
nevertheless
result
tcga
data
analysi
show
src
mrna
level
statist
correl
overal
diseasefre
surviv
patient
tnbc
phosphoryl
src
activ
src
associ
poor
diseasefre
surviv
patient
colorect
cancer
cervic
cancer
hou
et
al
kopetz
et
al
result
rais
possibl
src
activ
may
precis
way
determin
correl
diseas
tnbc
patient
studi
requir
verifi
idea
regard
mechan
srcenhanc
chemoresist
src
confer
aktmtor
activ
acut
myeloid
leukemia
cancer
stem
li
et
al
highli
associ
drug
resist
prietovila
et
al
silenc
src
reduc
express
aldehyd
dehydrogenas
isoform
cancer
stem
marker
sphere
format
lung
cancer
cell
lee
et
al
besid
src
phosphoryl
tyrosin
suppress
apoptosi
tsang
et
al
src
may
also
inhibit
apoptosi
via
directli
phosphoryl
tyrosin
crucial
protein
repair
dna
doublestrand
break
morii
et
al
result
suggest
src
could
activ
sever
pathway
caus
chemoresist
cancer
cell
src
increas
proinflammatori
cytokin
product
tumor
develop
activ
surviv
effector
chemoresist
su
et
al
tsai
et
al
includ
phosphoinositid
akt
dasatinib
shown
inhibit
growth
tnbc
cell
line
vitro
use
combin
standard
chemotherapi
cisplatin
use
singl
agent
finn
et
al
pathway
frequent
deregul
tnbc
inhibitor
pathway
develop
preclin
earli
phase
clinic
trial
massihnia
et
al
rapamycin
analog
temsirolimu
everolimu
deforolimu
inhibitor
mtor
undergo
clinic
evalu
treatment
varieti
cancer
includ
breast
cancer
minami
et
al
support
notion
signal
may
crucial
chemoresist
tnbc
cell
besid
chemoresist
tnbc
sever
mechan
might
involv
chemoresist
tnbc
report
previous
includ
abc
transport
efflux
ii
pathway
iii
increas
antiapoptosi
detoxif
protein
reilli
et
al
iv
gene
amplif
protooncogen
myc
wein
loi
howev
crosstalk
among
pathway
effect
pathway
srcmediat
chemoresist
cell
cultur
model
clinic
relev
would
need
studi
verifi
addit
wide
recogn
oncogen
variou
cancer
confirm
constitut
activ
tnbc
deng
et
al
xiong
et
al
knockdown
enhanc
cisplatininduc
apoptosi
ovarian
cancer
nonsmal
cell
lung
cancer
cell
yin
et
al
han
et
al
although
dasatinib
effect
cancer
cell
aberr
src
activ
zhang
yu
src
inhibitor
success
suppress
tumor
cancer
patient
use
alon
possibl
suitabl
biomark
monitor
src
activ
tumor
tissu
treatment
trigger
altern
rout
resist
src
inhibit
zhang
yu
result
suggest
axi
might
play
import
role
chemoresist
tnbc
cell
may
use
evalu
tumor
treat
src
inhibitor
chemotherapi
ydt
pfl
jyl
perform
experi
lfl
figur
b
syk
figur
cwh
chw
figur
perform
remain
experi
tcga
data
analyz
chl
htc
mh
cw
prepar
figur
interpret
data
wrote
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
